WEDNESDAY 7 DECEMBER 7.00 h Check in 8.00 h Opening Remarks by Raymond F. Schinazi 8.10 h Presentation of David Barry DART Achievement Award Raymond F. Schinazi, PhD, DSc - Emory University, USA 8.20 h David Barry DART Achievement Award Lecture: The Discovery of SIV and Development of Monkey Models for the Study of HIV/ AIDS Ronald C. Desrosiers, PhD - University of Miami, USA Session 1 Chair Cure Session (Sponsored by amfar) Rowena Johnston - amfar, USA Raymond F. Schinazi - Emory University, USA 8.50 h Controversies and Misconceptions in HIV Reservoir Research Mario Stevenson, PhD - University of Miami/GVN, USA 9.10 h HIV-1 Macrophage Reservoirs: Lessons from Host Macrophage Specific Restriction Factor, SAMHD1 Baek Kim, PhD - Emory University, USA 9.30 h Humanized Mice as Models in Drug Development for Antiviral Therapies J. Victor Garcia-Martinez, PhD - University of North Carolina, USA 9.50 h Sustained Virologic Control in SIV+ Macaques Siddappa Byrareddy, PhD - University of Nebraska Medical Center, USA 10.10 h Panel Discussion 10.25 h Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents D. Kulpa, Emory University, USA 10.35 h HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration R.M. Ribeiro, Los Alamos National Laboratory, USA Non- O_01 O_02 10.45 h Coffee break Session 2 New Drugs for HIV Baek Kim - Emory University, USA Ronald C. Desrosiers - University of Miami, USA 11.05 h State of the Art Lecture Integrase Inhibitors Today and Tomorrow Jay Grobler, PhD - Merck Inc., USA Non-
11.35 h Development of a New Class of Allosteric Inhibitors of HIV-1 Integrase with Promising Activity Against Resistance Mutations Eddy Arnold, PhD - Rutgers University, USA 11.55 h CryoEM Structures and Atomic Model of the HIV-1 Strand Transfer Complex Intasome Dmitry Lyumkis, PhD - Salk Institute, USA 12.15 h Panel Discussion 12.25 h Lunch break 14.00 h Free afternoon Session 3 Inflammation and Cure Mario Stevenson - University of Miami, USA David Thomas - Johns Hopkins School of Medicine, USA 17.30 h State of the Art Lecture Current Clinical Therapies for HIV Remission David Margolis, MD - University of North Carolina USA 18.00 h Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages Christina Gavegnano, PhD - Emory University, USA Non- Oral Abstract Presentation 18.20 h Anti HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages J. Tazi, Laboratoire coopératif ABIVAX-CNRS-UM, France Non- O_03 18.30 h Cure and Controversies Debate Baek Kim, PhD - Emory University, USA (Speaker) David Margolis, MD - University of North Carolina, USA (Speaker) Mario Stevenson, PhD - University of Miami, USA (Discussant) Charles Boucher, MD, PhD - Erasmus Medical Center, The Netherlands (Discussant) Rowena Johnston, PhD - amfar, USA (Discussant) Veronica Miller, PhD - Berkeley University, USA (Discussant) Non- 19.30 h Dinner
THURSDAY 8 DECEMBER Rowena Johnston - amfar, USA Charles Boucher - Erasmus Medical Center, The Netherlands 8.30 h Presentation of Gertrude Elion Distinguished Lecturer Award Rowena Johnston, PhD - amfar, USA 8.40 h Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease Mark Wainberg,PhD - McGill University, Canada Session 4 New Drugs and NeuroAIDS Ladislau Kovari - Wayne State University, USA Charles Boucher - Erasmus Medical Center, Holland 9.10 h Management of Neurocognitive Impairment of Aging Populations Living with HIV Scott Letendre, MD - University of California, USA 9.30 h EFdA (4'-Ethynyl-2-fluoro-2'-deoxyadenosine) a Powerful Nucleoside Analog for HIV Infections Hiroaki Mitsuya, MD, PhD - National Cancer Institute, USA 9.50 h Panel Discussion Non- Non- 10.20 h Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) B. Baugh, Janssen Research & Development LLC, USA 10.30 h Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V C. Callebaut, Gilead, Clinical Virology, USA Non- O_04 O_05 10.40 h Coffee break Session 5 Co-infections, Immunology and Public Health Raymond Schinazi - Emory University, USA Eddy Arnold - Rutgers University, USA 11.00 h Collateral Damage with Antiviral Therapy David Thomas, MD, MPH - Johns Hopkins School of Medicine, USA 11.20 h AAV Vector to Deliver Potent Broadly Neutralizing Antibody for Treatment Purpose Ronald C. Desrosiers, PhD - University of Miami, USA 11.40 h HIV Knowledge and Hope in Africa Carol A. Harris, MD - Albert Einstein College of Medicine, USA Non-
12.00 h State of the Art Lecture Phylogenetics and Intervention Strategies Richard Harrigan, PhD - British Columbia Centre for Excellence in HIV, Canada Oral Abstract Presentation 12.30 h Predicting Antiviral Drug Toxicity Using Contractility Analysis Of Human IPSC Derived Cardiomyocytes Brian D. Herman, Emory University School of Medicine, USA Non- O_08 12.40 h Lunch break 14.00 h Free afternoon FRIDAY 9 DECEMBER Session 6 Emerging Viruses I: Epidemiology, Pathogenesis & Treatment Hiroaki Mitsuya - National Institutes of Health, USA Mark Wainberg - McGill University, Canada 8.30 h State of the Art Lecture What Do We Really Know About Dengue Viruses Oscar Perng, PhD - National Cheng Kung University, Taiwan 9.00 h Insights into Viral Pathogenesis and Antiviral Strategies for Zika Alan Perelson, PhD - Los Alamos, USA 9.20 h Global Burden and Novel Treatment of Noroviruses Ladislau Kovari, PhD - Wayne State University, USA 9.40 h Zika Neuropathies Beyond Microcephaly Maurício Lacerda Nogueira, MD, PhD - Medicine School of São José do Rio Preto (FAMERP), Brazil Non- 10.00 h In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors Bryan D. Cox, Emory University, USA 10.10 h Jak 1/2 Inhibition Modulates Production of Replication Competent Zika Virus in Primary Human Hofbauer, Trophoblast and Neuroblastoma Cells Leda Bassit, Emory University, USA Non- O_06 O_07 10.20 h Coffee break
Session 7 Emerging Viruses II: Diagnosis and Treatment Alan Perelson - Los Alamos, USA Oscar Perng - National Cheng Kung University, Taiwan 10.40 h State of the Art Lecture Research efforts to combat ZIKA: The Miami experience David Watkins - University of Miami, USA 11.10 h Zika-Specific Antibodies for Prophylaxis and Detection David Watkins - University of Miami, USA 11.30 h Rapid Zika Detection for Resource-Limited Regions Mark Sharkey, PhD - Discidium/University of Miami, USA 11.50 h Closing Remarks: Outlook Over the Horizon Raymond F. Schinazi, PhD, DSc - Emory University, USA Lunch on your own (vouchers provided for those who stay until the end)